Nektar Therapeutics SEC filings NKTR

Nektar Therapeutics has 1,000 filings in SEC EDGAR's recent list, going back to Aug 5, 2015. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Nektar Therapeutics SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Oct 20, 2026 —
8-K Current report
Regulation FD disclosure
Oct 1, 2026 Oct 1, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) Sep 28, 2026 —
4 Insider transaction Sep 25, 2026 Sep 23, 2026
4 Insider transaction Sep 25, 2026 Sep 23, 2026
4 Insider transaction Sep 25, 2026 Sep 23, 2026
4 Insider transaction Sep 25, 2026 Sep 23, 2026
4 Insider transaction Sep 25, 2026 Sep 23, 2026
8-K Current report
Other events
Sep 25, 2026 Sep 24, 2026
8-K Current report
Regulation FD disclosure
Sep 8, 2026 Sep 8, 2026
4 Insider transaction Aug 20, 2026 Aug 18, 2026
4 Insider transaction Aug 20, 2026 Aug 18, 2026
144 Notice of proposed sale Aug 18, 2026 —
144 Notice of proposed sale Aug 18, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
S-8 Employee stock plan registration Aug 14, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 13, 2026 Aug 13, 2026
SCHEDULE 13G Ownership over 5% (passive) Jul 31, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Jul 29, 2026 —
4 Insider transaction Jul 24, 2026 Jul 24, 2026
4 Insider transaction Jul 24, 2026 Jul 24, 2026
4 Insider transaction Jul 2, 2026 Jun 30, 2026
144 Notice of proposed sale Jun 30, 2026 —
4 Insider transaction Jun 18, 2026 Jun 16, 2026
4 Insider transaction Jun 17, 2026 Jun 15, 2026
144 Notice of proposed sale Jun 17, 2026 —
144 Notice of proposed sale Jun 16, 2026 —
144 Notice of proposed sale Jun 15, 2026 —
8-K Current report
Shareholder vote results
Jun 5, 2026 Jun 5, 2026
3 Initial insider ownership May 26, 2026 May 15, 2026
4 Insider transaction May 21, 2026 May 19, 2026
4 Insider transaction May 21, 2026 May 19, 2026
144 Notice of proposed sale May 19, 2026 —
144 Notice of proposed sale May 19, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
424B5 Prospectus supplement May 8, 2026 —
8-K Current report
Material agreement, Officer or director change
May 8, 2026 May 8, 2026
10-Q Quarterly report May 8, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
SCHEDULE 13G/A Amended ownership over 5% (passive) May 6, 2026 —
ARS Annual report to shareholders Apr 24, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 24, 2026 —
DEF 14A Proxy statement Apr 24, 2026 Jun 4, 2026
8-K Current report
Material agreement, Other events
Apr 23, 2026 Apr 21, 2026
424B5 Prospectus supplement Apr 23, 2026 —
424B5 Prospectus supplement Apr 20, 2026 —
8-K Current report
Regulation FD disclosure
Apr 20, 2026 Apr 20, 2026
8-K Current report
Regulation FD disclosure, Other events
Apr 20, 2026 Apr 20, 2026
SCHEDULE 13G Ownership over 5% (passive) Apr 17, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Mar 27, 2026 —
144 Notice of proposed sale Mar 13, 2026 —
10-K Annual report Mar 13, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 12, 2026 Mar 12, 2026
SCHEDULE 13G Ownership over 5% (passive) Mar 6, 2026 —
4 Insider transaction Feb 20, 2026 Feb 18, 2026
4 Insider transaction Feb 20, 2026 Feb 18, 2026
144 Notice of proposed sale Feb 18, 2026 —
144 Notice of proposed sale Feb 18, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 13, 2026 —
8-K Current report
Material agreement, Other events
Feb 13, 2026 Feb 11, 2026
424B5 Prospectus supplement Feb 13, 2026 —
424B5 Prospectus supplement Feb 10, 2026 —
8-K Current report
Regulation FD disclosure
Feb 10, 2026 Feb 10, 2026
8-K Current report
Regulation FD disclosure, Other events
Feb 10, 2026 Feb 10, 2026
SCHEDULE 13G Ownership over 5% (passive) Jan 30, 2026 —
8-K Current report
Regulation FD disclosure
Jan 27, 2026 Jan 27, 2026
4 Insider transaction Jan 22, 2026 Jan 20, 2026
144 Notice of proposed sale Jan 20, 2026 —
4 Insider transaction Dec 23, 2025 Dec 22, 2025
4 Insider transaction Dec 23, 2025 Dec 22, 2025
8-K Current report
Regulation FD disclosure, Other events
Dec 16, 2025 Dec 16, 2025
4 Insider transaction Nov 25, 2025 Nov 21, 2025
4 Insider transaction Nov 25, 2025 Nov 21, 2025
4 Insider transaction Nov 25, 2025 Nov 21, 2025
144 Notice of proposed sale Nov 25, 2025 —
144 Notice of proposed sale Nov 25, 2025 —
144 Notice of proposed sale Nov 25, 2025 —
8-K Current report
Officer or director change
Nov 21, 2025 Nov 21, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Nov 13, 2025 —
S-8 Employee stock plan registration Nov 12, 2025 —
424B5 Prospectus supplement Nov 12, 2025 —
S-3ASR Automatic shelf registration Nov 12, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Nov 10, 2025 Nov 8, 2025
10-Q Quarterly report Nov 7, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 6, 2025 Nov 6, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 31, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 28, 2025 —
4 Insider transaction Oct 1, 2025 Sep 30, 2025
4 Insider transaction Oct 1, 2025 Sep 30, 2025
4 Insider transaction Oct 1, 2025 Sep 30, 2025
4 Insider transaction Oct 1, 2025 Sep 30, 2025
4 Insider transaction Oct 1, 2025 Sep 30, 2025
8-K Current report
Regulation FD disclosure, Other events
Sep 18, 2025 Sep 18, 2025
4 Insider transaction Sep 11, 2025 Sep 9, 2025
144 Notice of proposed sale Sep 9, 2025 —
4 Insider transaction Sep 8, 2025 Sep 4, 2025
4 Insider transaction Sep 8, 2025 Sep 4, 2025
144 Notice of proposed sale Sep 5, 2025 —
4 Insider transaction Sep 4, 2025 Sep 2, 2025
4 Insider transaction Sep 4, 2025 Sep 2, 2025
144 Notice of proposed sale Sep 4, 2025 —
144 Notice of proposed sale Sep 4, 2025 —
144 Notice of proposed sale Sep 2, 2025 —
144 Notice of proposed sale Sep 2, 2025 —
4 Insider transaction Aug 21, 2025 Aug 19, 2025
4 Insider transaction Aug 21, 2025 Aug 19, 2025
4 Insider transaction Aug 21, 2025 Aug 19, 2025
144 Notice of proposed sale Aug 19, 2025 —
144 Notice of proposed sale Aug 19, 2025 —
144 Notice of proposed sale Aug 19, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Aug 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2025 —
S-8 Employee stock plan registration Aug 8, 2025 —
10-Q Quarterly report Aug 8, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 18, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jul 9, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Jul 3, 2025 —
8-K Current report
Material agreement, Other events
Jul 1, 2025 Jun 30, 2025
424B5 Prospectus supplement Jul 1, 2025 —
424B5 Prospectus supplement Jun 30, 2025 —
8-K Current report
Other events
Jun 27, 2025 Jun 24, 2025
8-K Current report
Regulation FD disclosure, Other events
Jun 24, 2025 Jun 24, 2025
8-K Current report
Bylaw or fiscal year change
Jun 6, 2025 Jun 6, 2025
8-K Current report
Other events
Jun 4, 2025 Jun 4, 2025
8-K Current report
Shareholder vote results
May 28, 2025 May 23, 2025
4 Insider transaction May 21, 2025 May 19, 2025
4 Insider transaction May 21, 2025 May 19, 2025
4 Insider transaction May 21, 2025 May 19, 2025
144 Notice of proposed sale May 19, 2025 —
144 Notice of proposed sale May 19, 2025 —
144 Notice of proposed sale May 19, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
10-Q Quarterly report May 9, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 8, 2025 May 8, 2025
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
DEF 14A Proxy statement Apr 25, 2025 May 23, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 17, 2025 —
PRE 14A Preliminary proxy statement Apr 15, 2025 May 23, 2025
8-K Current report
Listing notice
Apr 4, 2025 Apr 3, 2025
EFFECT Filing Apr 1, 2025 —
8-K Current report
Material agreement
Mar 28, 2025 Mar 28, 2025
CORRESP Letter to the SEC Mar 28, 2025 —
S-3 Shelf registration Mar 28, 2025 —
UPLOAD Letter from the SEC Mar 20, 2025 —
DRSLTR Filing Mar 14, 2025 —
DRS Filing Mar 14, 2025 —
S-8 Employee stock plan registration Mar 14, 2025 —
10-K Annual report Mar 14, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 12, 2025 Mar 12, 2025
8-K Current report
Other events
Feb 24, 2025 Feb 24, 2025
4 Insider transaction Feb 21, 2025 Feb 19, 2025
4 Insider transaction Feb 21, 2025 Feb 19, 2025
4 Insider transaction Feb 21, 2025 Feb 19, 2025
144 Notice of proposed sale Feb 19, 2025 —
144 Notice of proposed sale Feb 19, 2025 —
144 Notice of proposed sale Feb 19, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
8-K Current report
Other events
Feb 4, 2025 Feb 4, 2025
5 Annual insider ownership Jan 17, 2025 Dec 31, 2024
5 Annual insider ownership Jan 17, 2025 Dec 31, 2024
5 Annual insider ownership Jan 17, 2025 Dec 31, 2024
5 Annual insider ownership Jan 17, 2025 Dec 31, 2024
5 Annual insider ownership Jan 17, 2025 Dec 31, 2024
4 Insider transaction Dec 26, 2024 Dec 23, 2024
144 Notice of proposed sale Dec 26, 2024 —
144 Notice of proposed sale Dec 23, 2024 —
4 Insider transaction Dec 20, 2024 Dec 19, 2024
4 Insider transaction Dec 19, 2024 Dec 17, 2024
144 Notice of proposed sale Dec 19, 2024 —
144 Notice of proposed sale Dec 18, 2024 —
4 Insider transaction Dec 17, 2024 Dec 13, 2024
4 Insider transaction Dec 17, 2024 Dec 13, 2024
4 Insider transaction Dec 17, 2024 Dec 13, 2024
144 Notice of proposed sale Dec 17, 2024 —
8-K Current report
Acquisition or sale of assets
Dec 2, 2024 Dec 2, 2024
4 Insider transaction Nov 20, 2024 Nov 19, 2024
4 Insider transaction Nov 20, 2024 Nov 19, 2024
4 Insider transaction Nov 20, 2024 Nov 19, 2024
144 Notice of proposed sale Nov 19, 2024 —
144 Notice of proposed sale Nov 19, 2024 —
144 Notice of proposed sale Nov 19, 2024 —
SC 13G Ownership over 5% (passive) Nov 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
SC 13G Ownership over 5% (passive) Nov 8, 2024 —
10-Q Quarterly report Nov 8, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 7, 2024 Nov 7, 2024
8-K Current report
Material agreement, Regulation FD disclosure
Nov 4, 2024 Nov 1, 2024
SC 13G Ownership over 5% (passive) Oct 22, 2024 —
4 Insider transaction Aug 20, 2024 Aug 19, 2024
4 Insider transaction Aug 20, 2024 Aug 19, 2024
4 Insider transaction Aug 20, 2024 Aug 19, 2024
144 Notice of proposed sale Aug 19, 2024 —
144 Notice of proposed sale Aug 19, 2024 —

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NKTR (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
906709
Former names
INHALE THERAPEUTIC SYSTEMS INC (until Jan 10, 2003); INHALE THERAPEUTIC SYSTEMS (until May 14, 1998)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.